Effect of Omega-3 Fatty Acids Supplementation on Homocysteine Level in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis

Overview

Journal J Res Pharm Pract

Date 2023 Feb 17

PMID 36798100

Authors

Tahereh Gholipur-Shahraki

Sahar Vahdat

Shiva Seirafian

Morteza Pourfarzam

Shirinsadat Badri

Affiliations

Soon will be listed here.

Abstract

Objective: One of the most common diseases with high morbidity and mortality rates is chronic kidney disease. Cardiovascular disease affects most patients with chronic kidney disorders, particularly patients undergoing dialysis; hence, appropriate prevention and management approaches are essential. This study aimed to evaluate the reduction of inflammatory biomarkers, especially homocysteine, by omega-3 fatty acids in peritoneal dialysis patients.

Methods: This study enrolled 60 peritoneal dialysis patients who met specified inclusion and exclusion criteria and were randomized to intervention or placebo groups. Omega-3 capsules were given at a dose of 3 g/d for 8 weeks. Inflammatory markers, including high-sensitivity C-reactive protein (hs-CRP), homocysteine, albumin, and lipid profile measured before and after the study.

Findings: Results of this trial revealed that the levels of homocysteine, hs-CRP, and albumin did not change significantly during the study. Analysis of lipid profiles before and after intervention showed omega-3 has no significant effect on the level of total cholesterol or low-density lipoprotein cholesterol; However, the level of triglyceride reduced remarkably ( = 0.002). In addition, serum levels of high-density lipoprotein cholesterol increased at the end of the study ( < 0.001).

Conclusion: Omega-3 does not seem to be able to change the inflammatory markers significantly, particularly homocysteine. More extensive trials must be conducted to better understand the impact of omega-3 on inflammatory and nutritional markers, particularly in peritoneal dialysis patients.

Citing Articles

Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes.

Stepanova N Biomedicines. 2024; 12(10).

PMID: 39457689 PMC: 11505255. DOI: 10.3390/biomedicines12102377.

References

Miller M, Langenberg P, Havas S . Impact of lowering triglycerides on raising HDL-C in hypertriglyceridemic and non-hypertriglyceridemic subjects. Int J Cardiol. 2006; 119(2):192-5. PMC: 1950669. DOI: 10.1016/j.ijcard.2006.07.132. View

Alfaddagh A, Martin S, Leucker T, Michos E, Blaha M, Lowenstein C . Inflammation and cardiovascular disease: From mechanisms to therapeutics. Am J Prev Cardiol. 2021; 4:100130. PMC: 8315628. DOI: 10.1016/j.ajpc.2020.100130. View

Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S . Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010; 341:c6273. PMC: 2993045. DOI: 10.1136/bmj.c6273. View

Schunck W, Konkel A, Fischer R, Weylandt K . Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases. Pharmacol Ther. 2017; 183:177-204. DOI: 10.1016/j.pharmthera.2017.10.016. View

Orringer C, Jacobson T, Maki K . National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019; 13(6):860-872. DOI: 10.1016/j.jacl.2019.10.014. View

Rolf N, Tenschert W, Lison A . Results of a long-term administration of omega-3 fatty acids in haemodialysis patients with dyslipoproteinaemia. Nephrol Dial Transplant. 1990; 5(9):797-801. DOI: 10.1093/ndt/5.9.797. View

Taheri S, Keyvandarian N, Moeinzadeh F, Mortazavi M, Naini A . The effect of omega-3 fatty acid supplementation on oxidative stress in continuous ambulatory peritoneal dialysis patients. Adv Biomed Res. 2014; 3:143. PMC: 4139980. DOI: 10.4103/2277-9175.135160. View

Xu T, Sun Y, Sun W, Yao L, Sun L, Liu L . Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease: a meta-analysis. Sci Rep. 2016; 6:39346. PMC: 5180246. DOI: 10.1038/srep39346. View

Vernaglione L, Cristofano C, Chimienti S . Omega-3 polyunsaturated fatty acids and proxies of cardiovascular disease in hemodialysis: a prospective cohort study. J Nephrol. 2008; 21(1):99-105. View

10.

Hu C, Yang M, Zhu X, Gao P, Yang S, Han Y . Effects of Omega-3 Fatty Acids on Markers of Inflammation in Patients With Chronic Kidney Disease: A Controversial Issue. Ther Apher Dial. 2017; 22(2):124-132. PMC: 5880693. DOI: 10.1111/1744-9987.12611. View

11.

Mullick A, Zaid U, Athanassious C, Lentz S, Rutledge J, Symons J . Hyperhomocysteinemia increases arterial permeability and stiffness in mice. Am J Physiol Regul Integr Comp Physiol. 2006; 291(5):R1349-54. DOI: 10.1152/ajpregu.00335.2006. View

12.

Donadio C, Tognotti D, Donadio E . Albumin modification and fragmentation in renal disease. Clin Chim Acta. 2011; 413(3-4):391-5. DOI: 10.1016/j.cca.2011.11.009. View

13.

Miller M, Ballantyne C, Bays H, Granowitz C, Doyle Jr R, Juliano R . Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Am J Cardiol. 2019; 124(5):696-701. DOI: 10.1016/j.amjcard.2019.05.057. View

14.

Suliman M, Stenvinkel P, Barany P, Qureshi A, Lindholm B . Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. Semin Nephrol. 2006; 26(1):14-9. DOI: 10.1016/j.semnephrol.2005.06.004. View

15.

Davidson M, Maki K, Bays H, Carter R, Ballantyne C . Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2011; 3(5):332-40. DOI: 10.1016/j.jacl.2009.08.001. View

16.

Gharekhani A, Khatami M, Dashti-Khavidaki S, Razeghi E, Abdollahi A, Hashemi-Nazari S . Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients. Daru. 2014; 22(1):11. PMC: 3922959. DOI: 10.1186/2008-2231-22-11. View

17.

Ziaie S, Polroudi Moghaddam M, Samadian F, Sistanizad M, Afzal G, Saffaei A . Omega-3 in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis, Effects on Inflammatory Markers and Lipid Profile. Iran J Kidney Dis. 2020; 14(2):126-132. View

18.

Capelli I, Cianciolo G, Gasperoni L, Zappulo F, Tondolo F, Cappuccilli M . Folic Acid and Vitamin B12 Administration in CKD, Why Not?. Nutrients. 2019; 11(2). PMC: 6413093. DOI: 10.3390/nu11020383. View

19.

Takamitsu Y, Nakanishi T . Association of endothelial dysfunction with sulfur amino acid metabolism in chronic renal failure. Am J Kidney Dis. 2001; 38(4 Suppl 1):S95-9. DOI: 10.1053/ajkd.2001.27413. View

20.

Giray B, Kan E, Bali M, Hincal F, Basaran N . The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients. Clin Chim Acta. 2003; 338(1-2):91-8. DOI: 10.1016/j.cccn.2003.07.020. View